Pfizer (PFE) Non-Current Deferred Tax Liability (2009 - 2026)

Pfizer (PFE) has reported Non-Current Deferred Tax Liability for 18 consecutive years, with $2.0 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 20.84% year-over-year to $2.0 billion in Q2 2026; TTM through Jun 2026 was $2.0 billion, a 20.84% decrease from a year earlier, with the FY2025 full-year figure at $2.4 billion, down 81.56% from the prior year.
• Non-Current Deferred Tax Liability was $2.0 billion for Q2 2026 at Pfizer, down from $2.4 billion in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $16.2 billion in Q4 2023 and troughed at $558.0 million in Q3 2022.
• A 5-year average of $3.8 billion and a median of $2.2 billion in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability plunged 86.59% in 2022 and soared 142.53% in 2025, its largest moves.
• Over 5 years, Non-Current Deferred Tax Liability stood at $9.5 billion in 2022, then soared by 69.89% to $16.2 billion in 2023, then dropped by 19.47% to $13.0 billion in 2024, then plunged by 81.56% to $2.4 billion in 2025, then fell by 18.2% to $2.0 billion in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $2.0 billion (Q2 2026), $2.4 billion (Q1 2026), and $2.4 billion (Q4 2025), per Business Quant data.